Management of acute myocardial infarction.
This article presents plans of therapy based on current knowledge of pathophysiologic mechanisms, taking into consideration the rapid changes in availability of new drugs (or new experiences with old drugs) and new therapeutic interventions. Persistence of ischemic pain in the acute phase, or its recurrence during early convalescence, is a signal of a high-risk state for additional coronary events, and aggressive measures are required to prevent them. The indications, and the role of invasive hemodynamic monitoring in the treatment of left ventricular failure and/or hypotension, are discussed.
D000787:Angina Pectoris / Q000628:therapy; D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000627:therapeutic use; D003289:Convalescence; D001026:Coronary Artery Bypass; D003325:Coronary Care Units; D004032:Diet; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006439:Hemodynamics; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000628:therapy; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D010102:Oxygen Inhalation Therapy; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents